Lithium: The pharmacodynamic actions of the amazing ion

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 3, 2013, Pages 163-176

  Brown, Kayleigh M ^a   Tracy, Derek K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

glycogen synthase kinase 3; inositol monophosphatase; lithium; pharmacology

Indexed keywords

GLUTAMATE RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; INOSITOL MONOPHOSPHATASE; LITHIUM; MAGNESIUM; PHOSPHATASE; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CIRCADIAN RHYTHM; DEGENERATIVE DISEASE; ENZYME INHIBITION; GRAY MATTER; HUMAN; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WHITE MATTER;

EID: 84997860352     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312471963     Document Type: Article

References (119)

1. Abe M. Herzog E. Block G. (2000) Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neuroreport 11: 3261–3264.
2. Agam G. Shamir A. Shaltiel G. Greenberg M. (2002) Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs. Bipolar Disord 4: 15–20.
3. Alessi D. Cohen P. (1998) Mechanism of activation and function of protein kinase B. Curr Opin Genetics Dev 8: 55–62.
4. Allison J. Stewart M. (1971) Reduced brain inositol in lithium-treated rats. Nat New Biol 233: 267–268.
5. Alvarez G. Munoz-Montano J. Satrustegui J. Avila J. Bogonez E. Diaz-Nido J. (2002) Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 4: 153–165.
6. Bauer M. Alda M. Priller J. Young L. (2003a) Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36: S250–S254.
7. Bauer M. Forsthoff A. Baethge C. Adli M. Berghofer A. Dopfmer S. et al. (2003b) Lithium augmentation therapy in refractory depression - Update 2002. Eur Arch Psychiatry Clin Neurosci 253: 132–139.
8. Bearden C. Thompson P. Dalwani M. Hayashi K. Lee A. Nicoletti M. et al. (2007) Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 62: 7–16.
9. Beaulieu J. Gainetdinov R. Caron M. (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49: 327–347.
10. Beaulieu J. Marion S. Rodriguiz R. Medvedev I. Sotnikova T. Ghisi V. et al. (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132: 125–136.
11. Beaulieu J. Sotnikova T. Marion S. Lefkowitz R. Gainetdinov R. Caron M. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122: 261–273.
12. Beaulieu J. Sotnikova T. Yao W. Kockeritz L. Woodgett J. Gainetdinov R. et al. (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101: 5099–5104.
13. Benedetti F. Radaelli D. Poletti S. Locatelli C. Falini A. Colombo C. et al. (2011) Opposite effects of suicidality and lithium on gray matter volumes in bipolar depression. J Affect Disord 135: 139–147.
14. Berridge M. Downes C. Hanley M. (1989) Neural and developmental actions of lithium - a unifying hypothesis. Cell 59: 411–419.
15. Berridge M. Irvine R. (1989) Inositol phosphates and cell signaling. Nature 341: 197–205.
16. Bowden C. (2000) Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 61: 35–40.
17. Burgess S. Geddes J. Hawton K. Townsend E. Jamison K. Goodwin G. (2001) Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev: CD003013.
18. Caccamo A. Majumder S. Richardson A. Strong R. Oddo S. (2010) Molecular Interplay between mTOR, A (beta), and tau: effects on cognitive impairments. J Biol Chem 285: 13107–13120.
19. Cade J. (1949) Lithium salts in the treatment of psychotic excitement. Med J Austral 2: 349–352.
20. Chalecka-Franaszek E. Chuang D. (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96: 8745–8750.
21. Chen G. Zeng W. Yuan P. Huang L. Jiang Y. Zhao Z. et al. (1999) The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72: 879–882.
22. Chiu C. Chuang D. (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128: 281–304.
23. Cipriani A. Pretty H. Hawton K. Geddes J. (2005) Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 162: 1805–1819.
24. Cleary C. Linde J. Hiscock K. Hadas I. Belmaker R. Agam G. et al. (2008) Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull 76: 469–473.
25. Cohen P. Frame S. (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769–776.
26. Coppen A. (2000) Lithium in unipolar depression and the prevention of suicide. J Clin Psychiatry 61: 52–56.
27. Crespo-Biel N. Camins A. Pallas M. Canudas A. (2009) Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology 56: 422–428.
28. Cross D. Alessi D. Cohen P. Andjelkovich M. Hemmings B. (1995) Inhibition of glycogen-synthase kinase-3 by insulin-mediated by protein-kinase-B. Nature 378: 785–789.
29. De Sarno P. Li X. Jope R. (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158–1164.
30. Doble B. Woodgett J. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175–1186.
31. Dudev T. Lim C. (2011) Competition between Li+ and Mg2+ in metalloproteins. Implications for lithium therapy. J Am Chem Soc 133: 9506–9515.
32. Engel T. Goni-Oliver P. Lucas J. Avila J. Hernandez F. (2006) Chronic lithium administration to FTDP-17 tau and GSK-3 beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99: 1445–1455.
33. Fang X. Yu S. Lu Y. Bast R. Woodgett J. Mills G. (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97: 11960–11965.
34. Fang X. Yu S. Tanyi J. Lu Y. Woodgett J. Mills G. (2002) Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22: 2099–2110.
35. Ferrie L. Young A. McQuade R. (2006) Effect of lithium and lithium withdrawal on potassium-evoked dopamine release and tyrosine hydroxylase expression in the rat. Int J Neuropsychopharmacol 9: 729–735.
36. Freland L. Beaulieu J. (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5: 1–7.
37. Garcia-Perez J. Avila J. Diaz-Nido J. (1998) Implication of cyclin-dependent kinases and glycogen synthase kinase 3 in the phosphorylation of microtubule-associated protein 1B in developing neuronal cells. J Neurosci Res 52: 445–452.
38. Geddes J. Burgess S. Hawton K. Jamison K. Goodwin G. (2004) Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161: 217–222.
39. Geddes J. Goodwin G. Rendell J. Azorin J. Cipriani A. Ostacher M. et al. (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375: 385–395.
40. Gershon S. Soares J. (1997) Current therapeutic profile of lithium. Arch Gen Psychiatry 54: 16–20.
41. Gould T. Einat H. Bhat R. Manji H. (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 7: 387–390.
42. Gould T. Manji H. (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30: 1223–1237.
43. Guo S. Arai K. Stins M. Chuang D. Lo E. (2009) Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 40: 652–655.
44. Haimovich A. Eliav U. Goldbourt A. (2012) Determination of the lithium binding site in inositol monophosphatase, the putative target for lithium therapy, by magic-angle-spinning solid-state NMR. J Am Chem Soc 134: 5647–5651.
45. Hallcher L. Sherman W. (1980) The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 255: 896–901.
46. Harwood A. (2005) Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry 10: 117–126.
47. Hong M. Chen D. Klein P. Lee V. (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272: 25326–25332.
48. Hughes K. Nikolakaki E. Plyte S. Totty N. Woodgett J. (1993) Modulation of the glycogen-synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12: 803–808.
49. Hunsberger J. Austin D. Henter I. Chen G. (2009) The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 11: 333–348.
50. Inkster B. Nichols T. Saemann P. Auer D. Holsboer F. Muglia P. et al. (2009) Association of GSK3 beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 66: 721–728.
51. Jacinto E. Facchinetti V. Liu D. Soto N. Wei S. Jung S. et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125–137.
52. Jones R. Arlidge J. Gillham R. Reagu S. van den Bree M. Taylor P. (2011) Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry 198: 93–98.
53. Jope R. (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24: 441–443.
54. Jope R. Johnson G. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95–102.
55. Kaidanovich-Beilin O. Milman A. Weizman A. Pick C. Eldar-Finkelman H. (2004) Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55: 781–784.
56. Kaidanovich-Beilin O. Woodgett J. (2011) GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 4: 1–25.
57. Kaladchibachi S. Doble B. Anthopoulos N. Woodgett J. Manoukian A. (2007) Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J Circadian Rhythms 5: 1–12.
58. Karege F. Perroud N. Burkhardt S. Schwald M. Ballmann E. La Harpe R. et al. (2007) Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3 beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 61: 240–245.
59. Kennedy N. Paykel E. (2004) Treatment and response in refractory depression: results from a specialist affective disorders service. J Affect Disord 81: 49–53.
60. Klein P. Melton D. (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93: 8455–8459.
61. Kockeritz L. Doble B. Patel S. Woodgett J. (2006) Glycogen synthase kinase-3 - An overview of an over-achieving protein kinase. Curr Drug Targets 7: 1377–1388.
62. Leech A. Baker G. Shute J. Cohen M. Gani D. (1993) Chemical and kinetic mechanism of the inositol monophosphatase reaction and its inhibition by Li+. Eur J Biochem 212: 693–704.
63. Lenox R. Hahn C. (2000) Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 61: 5–15.
64. Lenox R. Watson D. (1994) Lithium and the brain – a psychopharmacological strategy to a molecular-basis for manic-depressive illness. Clin Chem 40: 309–314.
65. Leroy K. Ando K. Heraud C. Yilmaz Z. Authelet M. Boeynaems J. et al. (2010) Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 19: 705–719.
66. Li J. Lu W. Beesley S. Loudon A. Meng Q. (2012) Lithium impacts on the amplitude and period of the molecular circadian clockwork. Plos One 7: 8.
67. Li X. Zhu W. Roh M. Friedman A. Rosborough K. Jope R. (2004) In vivo regulation of glycogen synthase kinase-3 beta (GSK3 beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29: 1426–1431.
68. Livingstone C. Rampes H. (2006) Lithium: a review of its metabolic adverse effects. J Psychopharmacol 20: 347–355.
69. Lloyd L. Giaroli G. Taylor D. Tracy D. (2011) Bipolar depression: clinically missed, pharmacologically mismanaged. Ther Adv Psychopharmacol 1: 153–162.
70. Lochhead P. Kinstrie R. Sibbet G. Rawjee T. Morrice N. Cleghon V. (2006) A chaperone-dependent GSK3 beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 24: 627–633.
71. Lovestone S. Davis D. Webster M. Kaech S. Brion J. Matus A. et al. (1999) Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 45: 995–1003.
72. Manji H. Chen G. (2002) PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 7: S46–S56.
73. Manji H. Lenox R. (1999) Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive Illness. Biol Psychiatry 46: 1328–1351.
74. Manji H. Moore G. Chen G. (2000a) Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61: 82–96.
75. Manji H. Moore G. Chen G. (2000b) Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 48: 740–754.
76. Marmol F. (2008) Lithium: bipolar disorder and neurodegenerative diseases. Possible cellular mechanisms of the therapeutic effects of lithium. Prog NeuroPsychopharmacol Biol Psych 32: 1761–1771.
77. Martinek S. Inonog S. Manoukian A. Young M. (2001) A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105: 769–779.
78. McKnight R. Adida M. Budge K. Stockton S. Goodwin G. Geddes J. (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379: 721–728.
79. McQuade R. Robinson S. (2012) Attenuation of presynaptic dopamine function contributes to the effects of lithium on GSK-3β phosphorylation, in preparation.
80. Mendes C. Mury F. Moreira E. Alberto F. Forlenza O. Dias-Neto E. et al. (2009) Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease. Eur Arch Psychiatry Clin Neurosci 259: 16–22.
81. Mohawk J. Miranda-Anaya M. Tataroglu O. Menaker M. (2009) Lithium and genetic inhibition of GSK3 beta enhance the effect of methamphetamine on circadian rhythms in the mouse. Behav Pharmacol 20: 174–183.
82. Monkul E. Matsuo K. Nicoletti M. Dierschke N. Hatch J. Dalwani M. et al. (2007) Prefrontal gray matter increases in healthy individuals after lithium treatment: A voxel-based morphometry study. Neurosci Lett 429: 7–11.
83. Moore G. Bebchuk J. Hasanat K. Chen G. Seraji-Bozorgzad N. Wilds I. et al. (2000a) Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2s neurotrophic effects? Biol Psychiatry 48: 1–8.
84. Moore G. Bebchuk J. Wilds I. Chen G. Menji H. (2000b) Lithium-induced increase in human brain grey matter. Lancet 356: 1241–1242.
85. Mora A. Sabio G. Risco A. Cuenda A. Alonso J. Soler G. et al. (2002) Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal 14: 557–562.
86. Munoz-Montano J. Moreno F. Avila J. DiazNido J. (1997) Lithium inhibits Alzheimers disease-like tau protein phosphorylation in neurons. FEBS Lett 411: 183–188.
87. Nemeroff C. (2000) Introduction - Fifty years of lithium use in the treatment of bipolar disorder. J Clin Psychiatry 61: 3–4.
88. O’Brien W. Harper A. Jove F. Woodgett J. Maretto S. Piccolo S. et al. (2004) Glycogen synthase kinase-3 beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24: 6791–6798.
89. O’Brien W. Huang J. Buccafusca R. Garskof J. Valvezan A. Berry G. et al. (2011) Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 121: 3756–3762.
90. Pan J. Lewis M. Ketterman J. Clore E. Riley M. Richards K. et al. (2011) AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology 36: 1397–1411.
91. Pasquali L. Busceti C. Fulceri F. Paparelli A. Fornai F. (2010) Intracellular pathways underlying the effects of lithium. Behav Pharmacol 21: 473–492.
92. Peineau S. Taghibiglou C. Bradley C. Wong T. Liu L. Lu J. et al. (2007) UP inhibits LTD in the hippocampus via regulation of GSK3 beta. Neuron 53: 703–717.
93. Perova T. Wasserman M. Li P. Warsh J. (2008) Hyperactive intracellular calcium dynamics in B lymphoblasts from patients with bipolar I disorder. Int J Neuropsychopharmacol 11: 185–196.
94. Phiel C. Klein P. (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789–813.
95. Polter A. Beurel E. Yang S. Garner R. Song L. Miller C. et al. (2010) Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35: 1761–1774.
96. Poolsup N. Po A. de Oliveira I. (2000) Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 25: 139–156.
97. Prickaerts J. Moechars D. Cryns K. Lenaerts I. van Craenendonck H. Goris I. et al. (2006) Transgenic mice overexpressing glycogen synthase kinase 3 beta: A putative model of hyperactivity and mania. J Neurosci 26: 9022–9029.
98. Roybal K. Theobold D. Graham A. DiNieri J. Russo S. Krishnan V. et al. (2007) Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A 104: 6406–6411.
99. Ryves W. Harwood A. (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280: 720–725.
100. Sarkar S. Floto R. Berger Z. Imarisio S. Cordenier A. Pasco M. et al. (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170: 1101–1111.
101. Sarkar S. Krishna G. Imarisio S. Saiki S. OKane C. Rubinsztein D. (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17: 170–178.
102. Sassi R. Nicoletti M. Brambilla P. Mallinger A. Frank E. Kupfer D. et al. (2002) Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 329: 243–245.
103. Shafti S. (2010) Olanzapine vs. lithium in management of acute mania. J Affect Disord 122: 273–276.
104. Shaltiel G. Shamir A. Nemanov L. Yaroslavsky Y. Nemets B. Ebstein R. et al. (2001) Inositol monophosphatase activity in brain and lymphocyte-derived cell lines of bipolar patients. World J Biol Psychiatry 2: 95–8.
105. Silverstone P. McGrath B. Kim H. (2005) Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 7: 1–10.
106. Soares J. Gershon S. (1998) The lithium ion: A foundation for psychopharmacological specificity. Neuropsychopharmacology 19: 167–182.
107. Soares J. Gershon S. (2000) The psychopharmacologic specificity of the lithium ion: Origins and trajectory. J Clin Psychiatry 61: 16–22.
108. Sourial-Bassillious N. Rydelius P. Aperia A. Aizman O. (2009) Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience 161: 1126–1134.
109. Stahl S. (2008) Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd edn (Essential Psychopharmacology Series). Cambridge: Cambridge University Press.
110. Stambolic V. Ruel L. Woodgett J. (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells. Curr Biol 6: 1664–1668.
111. Stambolic V. Woodgett J. (1994) Mitogen inactivation of glycogen-synthase kinase-3-beta in intact-cells via serine-9 phosphorylation. Biochem J 303: 701–704.
112. Sutherland C. Cohen P. (1994) The alpha-isoform of glycogen-synthase-kinase-3 from rabbit skeletal-muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 in-vitro. FEBS Lett 338: 37–42.
113. Sutherland C. Leighton I. Cohen P. (1993) Inactivation of glycogen-synthase-kinase-3-beta by phosphorylation - new kinase connections in insulin and growth-factor signaling. Biochem J 296: 15–19.
114. Tondo L. Baldessarini R. (2000) Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 61: 97–104.
115. Wasserman M. Corson T. Sibony D. Cooke R. Parikh S. Pennefather P. et al. (2004) Chronic lithium treatment attenuates intracellular calcium mobilization. Neuropsychopharmacology 29: 759–769.
116. Yasuda S. Liang M. Marinova Z. Yahyavi A. Chuang D. (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14: 51–59.
117. Young A. (2011) More good news about the magic ion: lithium may prevent dementia. Br J Psychiatry 198: 336–337.
118. Zhang F. Phiel C. Spece L. Gurvich N. Klein P. (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium – evidence for autoregulation of GSK-3. J Biol Chem 278: 33067–33077.
119. Zhu L. Wang S. Liu D. Yin Y. Tian Q. Wang X. et al. (2007) Activation of glycogen synthase kinase-3 inhibits long term potentiation with synapse-associated impairments. J Neurosci 27: 12211–12220.